Improvement of contusive spinal cord injury in rats by co-transplantation of gamma-aminobutyric acid-ergic cells and bone marrow stromal cells

Payam Mohammadgharibani, Taki Tiraihi, Alireza Delshad, Jalil Arabkheradmand, Taher Taheri

Research output: Contribution to journalArticle

Abstract

Background aims: Cell therapy is considered a promising option for treatment of spinal cord injury (SCI). The purpose ofthisstudy is to use combined therapy of bone marrow stromal cells (BMSCs) and BMSC-derived gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmitter cells (BDGCs) for the contusion model of SCI in rats. Methods: BDGCs were prepared from BMSCs by pre-inducing them with β-mercaptoethanol followed by retinoic acid and then inducing them by creatine. They were immunostained with BMSC, proneuronal, neural and GABA markers. The BDGCs were intraspinally transplanted into the contused rats, whereas the BMSCs were delivered intravenously. The animals were sacrificed after 12 weeks. Results: The Basso, Beattie and Bresnahan test showed improvement in the animals with the combined therapy compared with the untreated animals, the animals treated with GABAergic cells only and the animals that received BMSCs. The immunohistochemistry analysis of the tissue sections prepared from the animals receiving the combined therapy showed that the transplanted cells were engrafted and integrated into the injured spinal cord; in addition, a significant reduction was seen in the cavitation. Conclusions: The study shows that the combination of GABAergic cells with BMSCs can improve SCI.

Original languageEnglish (US)
Pages (from-to)1073-1085
Number of pages13
JournalCytotherapy
Volume15
Issue number9
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Mesenchymal Stromal Cells
Spinal Cord Injuries
gamma-Aminobutyric Acid
Transplantation
Contusions
Mercaptoethanol
Creatine
Therapeutics
Cell- and Tissue-Based Therapy
Tretinoin
Neurotransmitter Agents
Spinal Cord
Immunohistochemistry

Keywords

  • BMSCs
  • Combined therapy
  • GABAergic neurons
  • Spinal cord injury

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Transplantation
  • Cancer Research

Cite this

Improvement of contusive spinal cord injury in rats by co-transplantation of gamma-aminobutyric acid-ergic cells and bone marrow stromal cells. / Mohammadgharibani, Payam; Tiraihi, Taki; Delshad, Alireza; Arabkheradmand, Jalil; Taheri, Taher.

In: Cytotherapy, Vol. 15, No. 9, 01.09.2013, p. 1073-1085.

Research output: Contribution to journalArticle

Mohammadgharibani, Payam ; Tiraihi, Taki ; Delshad, Alireza ; Arabkheradmand, Jalil ; Taheri, Taher. / Improvement of contusive spinal cord injury in rats by co-transplantation of gamma-aminobutyric acid-ergic cells and bone marrow stromal cells. In: Cytotherapy. 2013 ; Vol. 15, No. 9. pp. 1073-1085.
@article{06afb49ec6ff42aebda738f51ca802e3,
title = "Improvement of contusive spinal cord injury in rats by co-transplantation of gamma-aminobutyric acid-ergic cells and bone marrow stromal cells",
abstract = "Background aims: Cell therapy is considered a promising option for treatment of spinal cord injury (SCI). The purpose ofthisstudy is to use combined therapy of bone marrow stromal cells (BMSCs) and BMSC-derived gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmitter cells (BDGCs) for the contusion model of SCI in rats. Methods: BDGCs were prepared from BMSCs by pre-inducing them with β-mercaptoethanol followed by retinoic acid and then inducing them by creatine. They were immunostained with BMSC, proneuronal, neural and GABA markers. The BDGCs were intraspinally transplanted into the contused rats, whereas the BMSCs were delivered intravenously. The animals were sacrificed after 12 weeks. Results: The Basso, Beattie and Bresnahan test showed improvement in the animals with the combined therapy compared with the untreated animals, the animals treated with GABAergic cells only and the animals that received BMSCs. The immunohistochemistry analysis of the tissue sections prepared from the animals receiving the combined therapy showed that the transplanted cells were engrafted and integrated into the injured spinal cord; in addition, a significant reduction was seen in the cavitation. Conclusions: The study shows that the combination of GABAergic cells with BMSCs can improve SCI.",
keywords = "BMSCs, Combined therapy, GABAergic neurons, Spinal cord injury",
author = "Payam Mohammadgharibani and Taki Tiraihi and Alireza Delshad and Jalil Arabkheradmand and Taher Taheri",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/j.jcyt.2013.05.002",
language = "English (US)",
volume = "15",
pages = "1073--1085",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Improvement of contusive spinal cord injury in rats by co-transplantation of gamma-aminobutyric acid-ergic cells and bone marrow stromal cells

AU - Mohammadgharibani, Payam

AU - Tiraihi, Taki

AU - Delshad, Alireza

AU - Arabkheradmand, Jalil

AU - Taheri, Taher

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Background aims: Cell therapy is considered a promising option for treatment of spinal cord injury (SCI). The purpose ofthisstudy is to use combined therapy of bone marrow stromal cells (BMSCs) and BMSC-derived gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmitter cells (BDGCs) for the contusion model of SCI in rats. Methods: BDGCs were prepared from BMSCs by pre-inducing them with β-mercaptoethanol followed by retinoic acid and then inducing them by creatine. They were immunostained with BMSC, proneuronal, neural and GABA markers. The BDGCs were intraspinally transplanted into the contused rats, whereas the BMSCs were delivered intravenously. The animals were sacrificed after 12 weeks. Results: The Basso, Beattie and Bresnahan test showed improvement in the animals with the combined therapy compared with the untreated animals, the animals treated with GABAergic cells only and the animals that received BMSCs. The immunohistochemistry analysis of the tissue sections prepared from the animals receiving the combined therapy showed that the transplanted cells were engrafted and integrated into the injured spinal cord; in addition, a significant reduction was seen in the cavitation. Conclusions: The study shows that the combination of GABAergic cells with BMSCs can improve SCI.

AB - Background aims: Cell therapy is considered a promising option for treatment of spinal cord injury (SCI). The purpose ofthisstudy is to use combined therapy of bone marrow stromal cells (BMSCs) and BMSC-derived gamma-aminobutyric acid (GABA)ergic inhibitory neurotransmitter cells (BDGCs) for the contusion model of SCI in rats. Methods: BDGCs were prepared from BMSCs by pre-inducing them with β-mercaptoethanol followed by retinoic acid and then inducing them by creatine. They were immunostained with BMSC, proneuronal, neural and GABA markers. The BDGCs were intraspinally transplanted into the contused rats, whereas the BMSCs were delivered intravenously. The animals were sacrificed after 12 weeks. Results: The Basso, Beattie and Bresnahan test showed improvement in the animals with the combined therapy compared with the untreated animals, the animals treated with GABAergic cells only and the animals that received BMSCs. The immunohistochemistry analysis of the tissue sections prepared from the animals receiving the combined therapy showed that the transplanted cells were engrafted and integrated into the injured spinal cord; in addition, a significant reduction was seen in the cavitation. Conclusions: The study shows that the combination of GABAergic cells with BMSCs can improve SCI.

KW - BMSCs

KW - Combined therapy

KW - GABAergic neurons

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=84881086901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881086901&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2013.05.002

DO - 10.1016/j.jcyt.2013.05.002

M3 - Article

C2 - 23806239

AN - SCOPUS:84881086901

VL - 15

SP - 1073

EP - 1085

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 9

ER -